Celemics, Inc.
- Home
- Companies
- Celemics, Inc.
- Products
- Celemics OncoRisk - Panel
Celemics OncoRisk - Panel
FromCelemics, Inc.
Celemics’ Oncorisk Panel is specifically designed to analyze hereditary cancer associated genes. The OncoRisk Panel targets 31 well-known oncogenes, leading to a reduction of totalsequencing cost compared to whole genome sequencing or whole exome sequencing. Additionally, if the gene of interest does not exist on the panel, it can be added separatelythrough our gene add-on service. This flexible design provides cost-effective sequencing results to every customer.
Most popular related searches
cancer associated gene
cancer-associated gene
precision medicine
genomic sequencing
cancer research
cancer treatment
oncogene
precise cancer treatment
oncology panels
oncology panel
- Comprehensive analysis of oncogenes
- Analyze 31 oncogenes associated with inherited cancer and precisely selected from Contract Research Organizations and numerous research studies
- Robust BI system for large deletion analysis
- Receive BI results for large deletion analysis provided by Celemics proprietary BI analysis system
- Used for Homologous Recombination Deficiency (HRD) testing
- Provides information for HRD grade computation to aid precision medicine for tumor treatment
- Market leading performance with sensitivity and specificity
- Detect all types of mutations with over 95% of sensitivity at 5% VAF
- 99.9% and 99.5% specificity for SNV and Indel, respectively
- Germline-related cancer research